Summary

How Merck Serono S.A. (ADR) maps according to Revere

Sector Level Count
Industries 1
Sectors 2
Subsectors 13
Product/Service Groups 36

Specific product example for Merck Serono S.A. (ADR)

Product Hierarchy
Healthcare
Biopharmaceuticals
Dermatology
Research/Preclinical Stage Products

Company Highlights:

Market Cap. n/a
Current Shares Outstnd. n/a
Contact Name
Contact Phone (22)7393000
City, State Geneva 20,
Dividends Per Common Share 0.00
Dividend Yield n/a
SI %SHOUT n/a
IH % Shares Outst. n/a
Number of Employees 4,775
Revenue Per Employee 620,955.7
Book Value Per Share 6.01
5 Year CAGR in Revenues % 15.30
5 Year CAGR in Earnings % 18.06
Asset Turnover 0.13
Fiscal Year End 12/31/2007
Next Reporting Period Mar, 2007

Business Description:

Merck Serono S.A., formerly Serono S.A. is a biotechnology company that discovers, develops, manufactures and markets therapeutic products for the treatment of human diseases in selected therapeutic areas. It focuses on specialized markets of neurology, reproductive health, growth and metabolism, dermatology, oncology and autoimmune diseases and has eight biotechnology products on the market. The Company has a global presence with operations in more than 40 countries, main production facilities in four countries and sales in over 90 countries. As of December 31, 2006, the Company had approximately 25 ongoing development projects, based on proteins, monoclonal antibodies and small molecules. In January 2007, Merck KGaA acquired majority interest in Serono S.A.

Products

Products Manufactured/Services Performed Details
Healthcare
Biopharmaceuticals
Dermatology
Research/Preclinical Stage Products

Products:

  • IL-20/IL-22 Receptor
Digestive System
Gastrointestinal Tract Disorders
Intestinal Disorders
Short Bowel Syndrome
Growth Hormones

Products:

  • Zorbtive (Somatropin)
Liver Disorders
Hepatitis
Hepatitis C
Chronic
Interferons

Products:

  • r-IFNB-1a (Recombinant Human Interferon Beta-1a)
Phase I/Phase II Clinical Stage Products

Products:

  • NI-0401 (Monoclonal Antibody)
  • Tadekinig Alpha (Recombinant Interleukin 18 Binding Protein(r-IL-18bp))
Endocrinology/Metabolism
Pituitary Gland Disorders
Lipodystrophy
Growth Hormones

Products:

  • Serostim (Somatropin)
Severe Short Stature
Growth Hormones

Products:

  • Saizen (Somatropin (rDNA Origin))
  • Geref (Sermorelin Acetate For Injection)
Turner`s Syndrome
Growth Hormones

Products:

  • Saizen (Somatropin (rDNA Origin))
Reproductive Disorders
Amenorrhea
Progestins

Products:

  • Crinone (Progesterone Gel)
Research/Preclinical Stage Products

Products:

  • PTP 1b Inhibitor
Immunology
Autoimmune Disorders
Multiple Sclerosis (MS)
Adenosine Deaminase Inhibitors

Products:

  • Oral Cladribine
Interferons

Products:

  • Rebif (Recombinant Interferon Beta-1a)
Topoisomerase II Inhibitors

Products:

  • Novantrone (Mitoxantrone Hydrochloride)
Phase I/Phase II Clinical Stage Products

Products:

  • JNK Inhibitor
  • NI-0401 (Monoclonal Antibody)
  • Tadekinig Alpha (Recombinant Interleukin 18 Binding Protein(r-IL-18bp))
  • Oral Cladribine
  • MMP-12 Inhibitor
  • Atacicept/TACI-Ig
Research/Preclinical Stage Products

Products:

  • NI-0501 (Monoclonal Antibody)
  • Interferon Beta:Fc
  • IL-20/IL-22 Receptor
  • NI-0401 (Monoclonal Antibody)
  • HuMax-TAC
Infectious Diseases
Viral
RNA Viruses
Flavivirus
Hepatitis C
Chronic
Interferons

Products:

  • r-IFNB-1a (Recombinant Human Interferon Beta-1a)
Musculoskeletal System
Phase I/Phase II Clinical Stage Products

Products:

  • Tadekinig Alpha (Recombinant Interleukin 18 Binding Protein(r-IL-18bp))
  • Atacicept/TACI-Ig
Research/Preclinical Stage Products

Products:

  • FGF-18
Neurology
Neuromuscular Disorders
Multiple Sclerosis (MS)
Adenosine Deaminase Inhibitors

Products:

  • Oral Cladribine
Interferons

Products:

  • Rebif (Recombinant Interferon Beta-1a)
Topoisomerase II Inhibitors

Products:

  • Novantrone (Mitoxantrone Hydrochloride)
Phase I/Phase II Clinical Stage Products

Products:

  • JNK Inhibitor
  • Oral Cladribine
  • MMP-12 Inhibitor
Research/Preclinical Stage Products

Products:

  • Osteopontin
Obstetrics/Gynecology
Female Genital Disorders
Infertility
Complications
Premature Ovulation
Gonadotropin Releasing Hormone (GnRH) Antagonists

Products:

  • Cetrotide (Cetrorelix Acetate)
Hormonal Treatments
Gonadotropins

Products:

  • Ovidrel/Ovidrel Pre-Filled Syringe (Choriogonadotropin Alfa)
  • Luveris (Lutropin alfa)
Ovulation Stimulating Agents

Products:

  • Serophene (Clomiphene Citrate)
  • Gonal-F Pen (Follitropin Alfa Injection)
  • Gonal-F (Follitropin Alfa)
Progestins

Products:

  • Crinone (Progesterone Gel)
Phase I/Phase II Clinical Stage Products

Products:

  • Anastrozole
  • Oxytocin Receptor Antagonist
  • Hyperglycosylated r-FSH
Research/Preclinical Stage Products

Products:

  • Prostanoid FP Receptor Antagonist
Oncology
Hematology
Lymphoma (Lymphatic Cancer)
Cutaneous T-Cell (CTCL)
Mycosis Fungoides
Monoclonal Antibodies

Products:

  • HuMax-CD4 (Zanolimumab)
Phase I/Phase II Clinical Stage Products

Products:

  • Adecatumumab (Monoclonal Antibody)
  • R763 (Aurora Kinase Inhibitor)
  • Atacicept/TACI-Ig
  • HuMax-CD4 (Zanolimumab)
Research/Preclinical Stage Products

Products:

  • IKK2 Inhibitor
Transplantation
Research/Preclinical Stage Products

Products:

  • NI-0401 (Monoclonal Antibody)
Urology
Male Genital Disorders
Testicular
Hypogonadism
Gonadotropins

Products:

  • Gonal-F (Follitropin Alfa)
Weight Management
Cachexia
Growth Hormones

Products:

  • Serostim (Somatropin)
Research/Preclinical Stage Products

Products:

  • PTP 1b Inhibitor
Medical Devices
Drug Delivery
Transdermal
Needle Free Injection Systems

Products:

  • cool.click
  • Rebiject/Rebiject II
  • one.click
  • SeroJet

Key Financials

FY Ends December
Period Length/End 3 months
ending
12/31/2006 		3 months
ending
09/30/2006 		3 months
ending
12/31/2005 		12 months
ending
12/31/2006 		12 months
ending
12/31/2005 		12 months
ending
12/31/2004
Total Revenue 739.2 699.1 669.9 2,804.9 2,586.4 2,458.0
Gross Margin % 88.51 89.93 90 89.38 89.72 87.63
Operating Income 134.0 199.6 164.2 736.6 -127.5 511.4
Operating Margin % 18.12 28.55 24.51 26.26 -4.93 20.81
Tax Rate % -42.46 14.84 13.55 4.05 -45.43 16.17
Income After Taxes 195.7 170.6 144.2 735.6 -105.3 481.3
Net Income Margin % 26.47 24.41 21.52 26.22 -4.07 19.58
F.D. EPS - Incl. Xord. Items 0.33 0.29 0.25 1.04 -0.37 0.73
Book Value Per Share 6.01 4.52 3.56 6.01 3.56 4.22

Ratios

P/R Ratio (TTM) n/a
P/E Ratio (TTM) n/a
Price To Free Cash Flow (TTM) n/a
Price To Book Value n/a
Net Assets to Market Cap. % n/a
Beta 1.56
Days to Sell Inventory 273.09
Current Ratio 2.38
Quick Ratio 1.69
Interest Coverage n/a
Debt to Market Cap. % n/a
Return on Equity % 19.97
Return on Assets % 13.13
Return on Invested Capital % 15.75

Major Competitors

Name Trailing Revenue P/R Ratio (TTM) P/E Ratio (TTM) 1 Year Return % Overlap
Average          

Notes:

Customers

Name Last Quarter Financial Stats 1 YR Price Performance %
Y/Y Revenue Growth % Sequential Revenue Growth % Y/Y Margin Growth % Sequential Margin Growth %
Average          

Notes:

Strategic Partners

Name Subtypes 1 YR Price Performance %

Business/Geographical Segments

Geographic Segments

Source:  ARS Apr 25, 2007
  External Revenue Total Revenue Operating Income/Loss Operating Margin (%)
Europe 360.5 48.7% 360.5 48.7% 164.2 52.1% 45.54%
North America 233.6 31.6% 233.6 31.6% 111.4 35.4% 47.71%
Middle East/Africa/Eastern Europe 65.8 8.9% 65.8 8.9% 13.8 4.4% 20.93%
Asia/Pacific-Oceania/Japan 43.2 5.8% 43.2 5.8% 17.5 5.6% 40.49%
Latin America 36.6 5.0% 36.6 5.0% 8.0 2.6% 21.92%
Segment Total 739.8 100.0% 739.8 100.0% 314.9 100.0% 42.57%
Unallocated 0.0   0.0   243.9    
Consolidated Total 739.8   739.8   558.8   75.54%